Routine pre-emptive screening programs
A well-equipped clinical pharmacogenomics laboratory has been established at the LUMC department of Pharmacy & Toxicology. This department has, in close collaboration with clinical departments, successfully implemented routine pre-emptive screening programs in:
- Oncology: patients receiving capecitabine or 5-fluorouracil tested for DPYD
- Nephrology: kidney transplant patients receiving tacrolimus tested for CYP3A5
- Psychiatry: patients with a therapy resistant depression, referred to LUMC for electroconvulsive therapy tested for CYP2D6, and CYP2C19.
Pharmacogenomics-based therapeutic (dose) guidelines
In collaboration with the Dutch Pharmacogenetics Working Group, pharmacogenomics-based therapeutic (dose) recommendations for 84 gene-drug pairs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, TPMT, DPYD, VKORC1, UGT1A1, HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden have been developed and integrated with systems for electronic drug prescribing and medication surveillance.